Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

VTRS · Q4 2025 Earnings

Viatris

Reported February 26, 2026

30-second summary

Viatris closed FY2025 at the top end of its raised guide ($14.3B revenue, $2.35 adjusted EPS) with adjusted EBITDA of $4.16B landing in the upper half of the $4.0–4.2B range, and delivered Q4 FY2025 revenue of $3.7B, +5% YoY — the strongest growth print of the year. But the FY2026 guide of ~2% revenue and EBITDA growth, paired with management explicitly recharacterizing 2026 as a "stabilization year" rather than the previously implied growth inflection, is the more important signal. The $650M gross / $400M net three-year cost program is now the operative lever; the previously deferred Q1 FY2026 investor event has materialized as this print's headline disclosure. GAAP operating cash flow guidance of $1.7–2.0B steps down from FY2025's $2.32B, but management attributes the move to ~$250M of one-time restructuring cash costs plus ~$320M residual divestiture-related costs/taxes and ~$110M Biocon-related taxes; on an underlying ex-restructuring/transaction basis, the $1.95–2.35B FCF guide is roughly flat-to-up vs FY2025's $2.2B ex-transaction FCF.

Headline numbers

EPS

Q4 FY2025

$0.57

Revenue

Q4 FY2025

$3.70B

+5.0% YoY

Gross margin

Q4 FY2025

31.0%

Free cash flow

Q4 FY2025

$0.62B

Operating margin

Q4 FY2025

-5.2%

Key financials

Q4 FY2025

Metric	Q4 FY2025	YoY	Q3 FY2025	QoQ
Revenue	$3.70B	+5.0%	$3.76B	-1.6%
EPS	$0.57	—	$0.67	-14.9%
Gross margin	31.0%	—	36.5%	-550bps
Operating margin	-5.2%	—	4.8%	-1000bps
Free cash flow	$0.62B	—	$0.66B	-5.8%

Guidance

Company beat FY2025 guidance at the high end and guided FY2026 to ~2% revenue and EBITDA growth, with strategic $650M cost savings to drive cash generation and balanced capital allocation.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	FY 2025	$13,900 - $14,300 million	$14,300 million	at high end of guide	Beat
Adjusted EPS	FY 2025	$2.25 - $2.35	$2.35	at high end of guide	Beat
Adjusted EBITDA	FY 2025	$4,000 - $4,200 million	$4,100 million	at midpoint of prior guide	Beat
Free Cash Flow	FY 2025	$1,850 - $2,150 million	$1,940 million	within guide range	Met
Operating Cash Flow (GAAP)	FY 2025	$2,200 - $2,450 million	$2,315.9 million	within guide range	Met

New guidance

Metric	Period	Guide	YoY
Revenue	FY 2026	$14,450 - $14,950 million	+1.1 to +4.5% YoY
Adjusted EPS	FY 2026	$2.33 - $2.47	-0.9 to +5.1% YoY
Adjusted EBITDA	FY 2026	$4,150 - $4,450 million	+1.2 to +8.5% YoY
Free Cash Flow (excluding transaction and restructuring costs)	FY 2026	$1,950 - $2,350 million	+0.5 to +21.1% YoY
Operating Cash Flow (GAAP)	FY 2026	$1,700 - $2,000 million	-26.6 to -13.6% YoY
New Product Revenues	FY 2026	$450 - $550 million	+38.9 to +69.8% YoY

Segment KPIs

Q4 FY2025

Segment	Q4 FY2025	YoY
Brands	$2.35B	+8.0%
Generics	$1.34B	—

Other KPIs

Q4 FY2025

Segment	Q4 FY2025	YoY
Developed Markets	$2.25B	+5.0%
Greater China	$0.57B	+10.0%
JANZ	$0.31B	-9.0%
Emerging Markets	$0.56B	+10.0%
Adjusted EBITDA	$1,003.1M	—
Adjusted Gross Margin	56.8%	—
New Product Revenues (Q4)	$78M	—
New Product Revenues (FY 2025)	$324M	—
New Product Revenues Guidance (FY 2026)	$450M-$550M	—
Operating Cash Flow (FY 2025)	$2,315.9M	—
Shareholder Returns (FY 2025)	>$1,000M	—
Expected Cost Savings (3-year)	$650M with $250M reinvestment	—

Management tone

Q2 "top-half hedge" → Q3 "raised and narrowed" → Q4 "stabilization year, savings as the lever."

Three quarters ago, management was hedging FY2025 with "top half of range." Last quarter, they raised and narrowed the same ranges. This quarter, they delivered at the top of those raised ranges — but pivoted the forward narrative away from operational growth and toward cost rationalization. CEO Smith's framing of 2026 as a stabilization year supported by savings realization — with structural expansion arriving as savings flow in — is a measurable downgrade from the "2026 inflection year" frame that earlier commentary implied; mid-single-digit growth has been deferred to 2027+.

The strategic review crystallized into a concrete $650M gross / $400M net program with $250M reinvestment over three years (phased ~30%/~30%/~40% across FY2026–FY2028), with immediate financial guide impact. Management framed this as essential post-divestiture recalibration rather than discretionary optimization.

The BD posture has hardened toward in-market revenue-accretive assets and away from early-stage pipeline deals. Japan is the test case, with three named acquisitions (Effexor GAD, Pitolisant, Spidey) intended to flip the segment from decline to growth by 2028.

Fast-acting meloxicam was reframed this quarter as a complex launch requiring a specialty sales force targeting orthopedic surgeons, dental surgeons, and podiatrists, with "potential partnerships to expand our reach" beyond those specialty targets. That doesn't break the thesis but does add execution complexity.

Recurring themes management leaned on this quarter:

Strategic review cost savings ($650M gross, $400M net) as enabler of reinvestment and margin stabilizationPipeline maturation with six regulatory decisions expected in 2026Japan market transformation via new asset acquisitions (Effexor, Pitolisant, Spidey)Base business stabilization at low single digits with growth from launches and BDIndoor facility remediation complete; minimal 2026 upside assumedFinancial flexibility for balanced capital allocation and selective in-market BD

Risks management surfaced:

Mandatory price decreases in Japan and structural market headwindsLoss of exclusivity impacts (Ameteza LOE mid-year Japan, isosulfan blue LOE North America)Gross margin pressure from ARV product mix recovery and lower-margin new productsFast-acting meloxicam access challenges and competitive dynamics in acute painTiming and successful execution of six regulatory decisions in 2026

Answers to last quarter's watch list

Q4 operating cash flow delivery. FY2025 OCF landed at $2,316M, within the trimmed $2.2–2.45B guide. The new concern shifts forward: FY2026 OCF guidance of $1.7–2.0B is a step-down, but management attributes it to one-time restructuring cash, divestiture-related taxes, and Biocon taxes — not underlying cash generation.

Resolved positively

Q1 FY2026 investor event substance. The strategic review has been quantified ahead of the March 19, 2026 investor event: $650M gross cost savings, $400M net after $250M reinvestment, over a three-year horizon phased ~30%/~30%/~40%, with FY2026 guide already embedding the early benefits.

Resolved positively

Indore FDA re-inspection date. No specific re-inspection date was disclosed; management met with FDA in November 2025 and said they will be ready for re-inspection this year, but timing is at agency discretion. Operational redundancies and alternative supply sources are in place; less than 1% of Indore recovery is baked into FY2026 guidance.

Continue monitoring

Meloxicam NDA submission by year-end. Management confirmed a positive pre-NDA meeting with FDA in January 2026 and guided to filing the NDA the day after the call. The product is now characterized as a complex specialty launch requiring a dedicated sales force and potential partnerships. The qualitative re-framing toward specialty-focus is a modest negative versus the Q3 FY2025 "we can do this ourselves" stance, but the filing is on track. Status: Resolved positively on filing; watch the commercial framing

Q4 new product revenue. Q4 FY2025 came in at $78M, leaving FY2025 at $324M. Management has guided FY2026 new product revenue to $450–550M, which now requires the six pending regulatory decisions to deliver.

Continue monitoring

What to watch into next quarter

March 19, 2026 investor event. Long-term revenue and earnings growth outlook, portfolio strategy across generics, established brands and innovative brands, R&D capabilities deep-dive. Watch for any quantification of the mid-single-digit growth path Smith has referenced.

FY2026 GAAP OCF trajectory. Management attributes the step-down to one-time items; watch Q1 FY2026 OCF for whether the restructuring/tax cash outflows front-load as described or whether the gap signals something beyond cost-program timing. Mistras flagged Q1 as the lowest quarter for FCF.

New product revenue Q1 ramp. FY2026 guide of $450–550M against FY2025's $324M requires meaningful step-up. Q1 print is the first read.

Regulatory decisions cadence. Six pending decisions in 2026 — Effexor GAD Japan (March), low-dose estrogen weekly patch (PDUFA July 30, 2026), MR-141 presbyopia (PDUFA October 17, 2026), Pitolisant OSAS and narcolepsy Japan (2H 2026), sotagliflozin Australia/Canada. Plus fast-acting meloxicam post-NDA filing.

Indore import alert resolution. Whether the FDA formally clears the import alert in 1H 2026 determines if Generics returns to positive YoY. Management says less than 1% baked into FY2026.

Japan acquisition integration. Effexor GAD, Pitolisant, and Spidey are now the named assets meant to flip JANZ from decline to growth by 2028. Watch for revenue contribution disclosure and whether JANZ YoY narrows from -9%, against the headwinds of Amitiza LOE mid-year.

Capital allocation tilt. With over $2.5B of deployable cash including Biocon proceeds, $400M net annual cost savings ramping, and BD now explicitly skewed to in-market accretive assets, watch whether Viatris executes a near-term deal, pays down debt (Mistras flagged this as a priority to keep leverage at 2.8–3.2x), or continues leaning on buybacks and dividend.

Sources

Viatris Q4 FY2025 Earnings Release, filed with SEC: https://www.sec.gov/Archives/edgar/data/1792044/000179204426000010/exhibit991-4q25earningsrel.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.